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ABSTRACT 
 
The synthesis of inorganic oxide material by a sol-gel technique through the formation 
of colloidal suspension (sol) and gelation of the sol into the gel enables incorporation 
of heat-sensitive active substances into the material during processing. Sol can be 
further processed into various forms, such as monoliths, fibers, coatings or 
microparticles. This versatile technique has recently been investigated in diagnostics as 
well as in pharmaceutical applications. 
 
The general objective of this study was to evaluate sol-gel derived silica gel as an 
implantable (monoliths) or injectable (microparticles) biodegradable carrier for 
controlled drug delivery. Sol-gel derived silica gel monoliths were prepared by casting 
while microparticles were prepared by spray drying. The effect of various synthesis 
parameters on the release rate of two model drugs, toremifene citrate and 
dexmedetomidine hydrochloride from monoliths and microparticles, was studied in 
vitro. In addition, the in vivo release of toremifene from subcutaneously administered 
monoliths, the degradation of monoliths and the tissue effects of silica gel were 
estimated in mice. Pharmakokinetic parameters of dexmedetomidine were evaluated in 
dogs after subcutaneous administration of dexmedetomidine hydrochloride in 
monoliths and microparticles. 
  
In vitro release of dexmedetomidine from silica gel and degradation of the silica gel 
was controlled by modifying processing parameters, e.g. water/tetraethoxysilane 
(TEOS) ratio, pH, by alkyl-substitution or by using spray drying instead of casting as 
the manufacturing method. The release of dexmedetomidine was slowest from silica 
xerogel monoliths and microparticles prepared at the isoelectric point (IEP) of silica. 
Decreasing the water/TEOS ratio either increased (monoliths) or decreased 
(microparticles) the release rate of dexmedetomidine. Since alkyl-substituted silica gel 
was more hydrophobic than 100% TEOS based silica, the release rate of 
dexmedetomidine decreased. The release of model drugs typically corresponded either 
to the square root of time kinetics or zero-order kinetics with simultaneous degradation 
of the silica gel matrix.  
 
The silica xerogel materials used were biodegradable and did not cause any adverse 
effects in the surrounding tissue or various organs in the preliminary study with mice. 
Sustained release was achieved with toremifene in mice and with dexmedetomidine in 
dogs. Silica gel formulation giving typical toremifene-related changes in the mouse 
uterus for more than six weeks and a formulation that produced an effective serum 
level of dexmedetomidine in a dog for at least 24 hours were developed. Silica xerogel 
was shown to be suitable for controlled delivery of drug substances both as an 
implantable and an injectable drug delivery system.   
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ABBREVIATIONS 
 
AUC   area under the concentration vs. time curve 
C0   total amount of drug in polymer 
Cs   solubility of drug in polymer 
Cmax   maximum concentration of drug substance in serum 
CH3COOH  acetic acid 
D   diffusional coefficient of the drug in the polymer 
DMDES   dimethyl(diethoxy)silane 
ε   porosity factor 
ETES   ethyl(triethoxy)silane 
FDA   U.S. Food and Drug Administration 
3H   tritium  
HCl   hydrochloric acid 
IEP   isoelectric point 
LD50   lethal dose, 50%   
Log Papp. logarithm of apparent partition coefficient (octanol/water) 
METES   methyl(triethoxy)silane 
Mt/M∞   fractional released amount of drug 
NaOH   natriumhydroxide 
NH4OH   ammoniumhydroxide 
NIH   National Institute of Health 
PEG   polyethyleneglycol 
PGA   poly(glycolic acid) 
pKa   ionisation constant/protonisation constant 
PLA   poly(lactic acid) 
PLGA   poly(lactic acid-glycolic acid)copolymer 
r   water/alkoxide ratio   
SBF   simulated body fluid 
SDS   sodium dodecyl sulphate 
SEM   scanning electron microscopy 
Si-O-   deprotonated silanol group 
Si-OH   silanol group 
Si(OH)4   silicic acid 
SiO2   silicon dioxide (silica) 
Si-O-Si   siloxane group 
SSA   specific surface area 
τ   tortuosity factor 
TEOS   tetraethoxysilane 
Tmax   time of maximum concentration 
TMOS   tetramethoxysilane 
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1. INTRODUCTION 
 
Several drugs that are used for treatment of diseases can not be administered through 
the gastrointestinal tract due to their poor physicochemical properties or due to a high 
first-pass metabolism in the liver or degradation in the acidic atmosphere of the 
stomach. Digestive enzymes in the intestine or enzymes in the gut wall are responsible 
for the presystemic degradation of many drugs. Conventional administration of such 
drugs by repetitive injections is inconvenient and causes fluctuation of the blood drug 
level. The administration of drug by implantation or injection as a polymeric drug 
delivery system provides advantages over conventional drug therapies. The entire drug 
dose needed for a desired period of time is administered at one time and released in a 
controlled manner. Other potential advantages include drug targeting, improved 
compliance and comfort. Polymeric systems also protect biologically sensitive active 
agents, e.g. proteins and peptides from degradation in the human body. On the other 
hand, incorporating highly potential drugs, like doxorubicin or nitrosoureas in a 
polymer matrix, decrease toxicity to several organs (Langer and Peppas, 1981, Langer, 
1990). The development of modern drug delivery technology has led to sophisticated 
systems that allow drug targeting and a sustained or controlled release of drug 
substances (Langer, 1998, Santini et al., 1999). 
 
The availability of various types of polymers generally referred to as biomaterials that 
can be introduced into the body without being rejected due to the inflammation 
process at the implantation site, make such an approach possible. These polymers 
control the rate of drug release by remaining intact while the drug diffuses out from 
the matrix or by releasing the drug by simultaneous degradation of the matrix. Drug 
release mechanisms depend on the degradation behaviour of the polymer. A diffusion 
controlled release of drug substance is achieved if the drug substance is released prior 
to degradation of the polymer undergoing homogenous degradation throughout the 
polymer matrix. Zero order release of the drug substance is attained if the drug 
substance is released simultaneously with polymers eroding from the surface 
(heterogenously) (Heller, 1980, Langer, 1980, Baker, 1987, Langer, 1993).   
 
In recent years, sol-gel method has attracted many researchers (Böttcher et al., 1998, 
Jokinen et al., 1998, Peltola et al., 1998, Falaize et al., 1999, Ahola et al., 2001). The 
name refers to a low-temperature method using chemical precursors that can produce 
homogenous and pure ceramics and glasses. Recently, biotechnology applications, 
where biomolecules (such as proteins, enzymes, antibodies etc.) are incorporated into 
sol-gel matrix, have been extensively studied (Braun et al., 1990, Lev, 1992). 
Applications include biochemical process monitoring, environmental testing, food 
processing and drug delivery for medicine. Sol-gel glasses have been used as matrix 
for catalysts, in hybrid materials, such as ceramic-polymer, ceramic-metal composites 
or biosensors in diagnostic applications (Braun et al., 1990, Lev et al., 1995,). In 1983 
Unger and co-workers introduced the idea using sol-gel derived silica gel in drug 
delivery applications (Unger et al., 1983). In addition, sol-gel based materials are 
bioactive i.e. they bond to bone and have osteoconductive properties and can be used 
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in biomedical and dental applications (Klein et al., 1995, Wilson et al., 1995, 
Suominen and Kinnunen, 1996, Stoor et al., 1999).  
 
The aim of the present thesis was to develop an implantable or injectable sol-gel 
derived silica xerogel formulation for the controlled release of drug substances using 
dexmedetomidine hydrochloride and toremifene citrate as model drugs. The aim was 
to attain formulations giving a few days effect for dexmedetomidine conventionally 
used as intramuscular bolus injection in premedication of anaesthesia and an effect of 
several months for toremifene used ordinarily as oral medication for long term 
treatment of metastatic breast cancer.  
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2. REVIEW OF LITERATURE 
 
2.1. BIOMATERIALS 
 
Regarding their use in medicine, biomaterials can be divided mainly into three classes: 
scaffolds for tissue engineering, load bearing applications for surgery and drug 
delivery systems (Ikada, 1999, Langer, 1999). Biomaterials should be biocompatible 
without any toxic, inflammatory, carcinogenic and immunogenic response. 
Accordingly, biomaterials can be divided into biotolerant, bioinert, biodegradable and 
bioactive materials (Heimke and Griss, 1983). They include polymers, metals, 
ceramics and composite materials. 
 
Tissue engineering involves tissue regeneration and tissue substitution, such as 
artificial organs (Ikada, 1999, Langer, 1999). Scaffolds for tissue engineering should 
provide space and substrate for cell differentiation and proliferation in the body. 
Transplanted cells encapsulated in an artificial scaffold might avoid destruction by the 
immune system eliminating the need for lifelong immunosuppression.  
 
Several surgical applications exist, such as sutures, membranes to cover bone defects, 
adhesives as well as ostheosynthesis pins, screws and plates in maxillofacial surgery. 
Most of the classical materials, such as steel, titanium and aluminium are intended to 
remain chemically inert in contact with human tissue. In contrast, bioactive materials, 
such as bioactive glass and sol-gel derived silica gel, form strong bonds with the 
surrounding tissue, e.g. bone and even promote growth of new tissue. Professor Hench 
launched in his pioneering work in the early 1970s a bioactive glass called Bioglass® 
(Hench et al., 1971), which is later used to replace bone in the middle ear or to fill 
defects in the jaw (Wilson et al., 1995). Bioactive glass has also been used in the 
treatment of facial injuries to replace the bone supporting the eye (Suominen and 
Kinnunen, 1996). Bioactive glass granules seem to provide promising option in 
odontology, where it can be used to fill defects associated with periodontal disease. It 
can also be used in frontal sinusitis and in special type of rhinitis (Peltola et al., 1998, 
Stoor et al., 1999). Biodegradable polymers, such as poly(lactic acid) (PLA) used for 
self-dissolving sutures and for fracture fixation have the advantage that they do not 
have to be surgically removed afterwards (Törmälä et al., 1998).  
 
The concept of biodegradation is also used in polymeric drug delivery systems, which 
should release a therapeutic agent in a controlled manner during a predetermined 
period (Langer, 1980, Baker, 1987, Nitsch and Banakar, 1994). Implant systems are 
used to provide sustained drug release for long-term systemic therapy, such as 
hormone replacement therapy or cancer therapy (Okada et al., 1988, Brem et al., 1991, 
Okada et al., 1994, Johnson et al., 1997). Although biodegradable polymers are widely 
studied only a few implantable or injectable drug products are commercially available. 
They are based mainly on PLA and poly(glycolic acid) (PGA) or their copolymers 
(Pitt et al., 1979, Okada et al., 1988, Okada et al., 1994, Johnson et al., 1997, 
Lemmouchi and Schacht, 1997, Kumar and Kumar, 2001). Implantable products based 
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on poly(anhydride)  for treatment of glioma and osteomyelitis are also commercially 
available (Brem et al., 1991, Domb et al., 1997).  
 
 
2.2. DRUG RELEASE MECHANISMS FROM POLYMERIC DEVICES 
 
Drug release from a controlled release system can be achieved by several mechanisms, 
such as diffusion through a rate-controlling membrane, by osmosis, ion exchange or 
by degradation of the matrix (Langer, 1990, Park et al., 1993, Nitsch and Banakar, 
1994, Göpferich and Langer, 1995).  
 
2.2.1. Diffusion controlled release from non-degradable systems 
 
Diffusion controlled systems can be divided into non-degradable reservoirs and 
monolithic devices (Baker and Lonsdale, 1974, Park et al., 1993). Reservoir systems 
provide constant release of a drug over a substantial period. In this system, a core of 
drug is surrounded by a polymer film which serves as diffusion barrier and the release 
of the drug occurs through this polymer membrane. As long as the drug concentration 
inside the film stays constant, the drug release obeys zero order kinetics. Ocusert 
(pilocarpine) and Progestasert (progesterone), for instance, are membrane-enclosed 
reservoir systems in commercial use.  
 
In monolithic devices of various shapes, the active agent is either dispersed or 
dissolved in the polymer matrix. In both cases drug diffusion through the polymer 
matrix is the rate limiting step and the release rates are determined by the choice of the 
polymer and its consequent effect on the diffusion and partition coefficient of the drug 
(Baker, 1987). 
 
Mathematical treatment of diffusion depends on whether the drug is dissolved or 
dispersed in the polymer.  In a matrix system, where the drug is dissolved in the 
polymer matrix, the release follows Fick´s law. The following equation describes drug 
release from a slab-shaped device: 
 
2/1
20
4 


=
h
Dt
M
Mt
π        (1) 
 
Mt/M0 is the fractional released amount of drug,  D is the diffusion coefficient of a 
drug in the matrix, h is the thickness of the slab device and t is time. This equation is 
valid for the release of the first 60 percent of the drug total (early time approximation). 
Thereafter the release kinetics follow first order kinetics (late time approximation). 
The reason for a decrease in the release rate is an increase in the diffusional path 
length (Baker and Lonsdale, 1974, Langer, 1980, Park et al., 1993). This problem can 
be avoided by using special geometry that provide increasing surface areas over time 
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(Langer, 1980). Mathematical expressions describing the release from other 
geometries can be found in literature (Baker, 1987). 
 
Higuchi developed an equation for the release of solid drugs dispersed in matrix 
dosage systems, from which the drug substance diffuses through non-porous polymer 
(Baker, 1987). Drug release is affected, apart from the geometry of the device, also by 
the concentration of drug. Drug release follows square root of time kinetics until the 
concentration in the matrix falls below the saturation value (C0>> Cs).  
 
2/1
02
2


=
t
CDCA
dt
dM st        (2) 
 
In this equation dM/dt is the release rate of drug, A is the total area of the slab (both 
sides), D is the diffusion coefficient of the drug in the matrix, Cs is the solubility of the 
drug in a polymeric matrix, C0 is the total amount of drug (dissolved plus dispersed) in 
unit volume of the matrix and t is time. In monolithic systems where excess drug is 
dispersed, the drug release rate increases with increasing drug concentration. The 
Higuchi expression is a good predictor of release rates from systems containing 5 to 
10 vol% of active agent.  
 
At higher drug concentrations, drug particles are in contact with each other and the 
drug is released by diffusion through the water filled pores. (Baker and Lonsdale, 
1974, Baker, 1987). The diffusion of drug from a porous matrix is described by a 
second form of the Higuchi equation. 
 
( ) 2/102 

 −= tCCCDQ ssετ
ε
     (3) 
In this case the amount of drug released per unit area of the matrix, Q, depends on the 
diffusion coefficient of the drug in the matrix (D), its solubility in the polymeric 
matrix (Cs), the total amount of the drug (dissolved plus dispersed) in unit volume of 
the matrix (C0), the porosity factor (ε) and the tortuosity factor (τ) of the matrix and 
time (t) (Langer, 1980, Baker, 1987). 
 
2.2.2. Solvent activation controlled systems 
 
In a solvent activation controlled system, the active agent is dissolved or dispersed 
within a polymeric matrix or is surrounded by a polymer and is generally not able to 
diffuse through the matrix. Permeation of the moving dissolution medium through the 
polymer controls the release behaviour of drugs from these systems (Langer and 
Peppas, 1981, Baker, 1987, Leong and Langer, 1987). Solvent controlled systems can 
be divided in two types; osmotic systems and swelling controlled systems. Drug 
release from the swelling polymer follows Fick´s law, when penetration of water into 
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the polymer is rapid as compared to drug diffusion, whereas non-Fickian diffusion is 
achieved when drug diffusion and the solvent induced relaxations in the polymer are 
within the same range. When drug diffusion is rapid compared to the constant rate of 
solvent induced relaxation and swelling in the polymer, zero-order drug release is 
achieved and drug release is referred to as Case II transport (Baker, 1987). An osmotic 
system is constructed by enclosing a drug in a semipermeable membrane equipped 
with an orifice. The release rate of drug is governed by the nature of the membrane 
and the osmotic activity of the drug core. A constant release is maintained as long as 
the drug core remains saturated (Leong and Langer, 1987). 
 
2.2.3. Biodegradable systems 
 
The mechanism of biodegradation and drug release from biodegradable controlled 
release systems can be described in terms of three basic parameters. To begin with, the 
type of the hydrolytically unstable linkage in the polymer, affects the design of the 
system and next, the position of the labile group in the polymer is important. Secondly 
the way the biodegradable polymer degrades, either at the surface or uniformly 
throughout the matrix, affects device performance substantially. The third significant 
factor is the device design. The active agent may be covalently attached to the 
polymer backbone and is released as the bond between drug and polymer cleaves. The 
active agent may also be dispersed or dissolved into a biodegradable polymer matrix 
in the same way it is in a monolithic system made from non-biodegradable polymer 
and the release is controlled by diffusion, by a combination of diffusion and erosion or 
solely by biodegradation of the matrix (Baker, 1987, Siepmann and Göpferich, 2001). 
 
Biodegradable polymers are divided in homogenous (bulk) and heterogeneous 
(surface eroding) degrading polymers. These mechanisms are the extreme cases and 
most biodegradable polymer systems constitute a combination of the two types of 
mechanisms (Baker, 1987, Siepmann and Göpferich, 2001). Degradation is the 
process of polymer scission by the cleavage of bonds in the polymer backbone. 
Degradation leads to size reduction of the polymer chains. Erosion is the mass loss of 
the polymer matrix (Göpferich, 1997, Siepmann and Göpferich, 2001). 
 
Homogenous (bulk) degradation appears to be the most common polymer degradation 
mechanism, where the polymer degrades homogeneously throughout the matrix. The 
hydrolysis of bulk degrading polymers usually proceeds by losing molecular weight at 
first, followed by loss of mass in the second stage when molecular weight has 
decreased to 15 000 g/mol or less. (Pitt et al., 1981). The biodegradation rate can be 
changed by changing the composition of the polymer but not by changing the size or 
shape of it (Tamada and Langer, 1993, Grizzi et al., 1995).  
 
Drug release from a matrix undergoing homogenous degradation may be governed by 
the equations derived from simple diffusion-controlled systems if the drug diffuses 
rapidly from the device before degradation of the matrix begins (figure 1). However, 
bulk degradation causes difficulties in the control of drug release, because the release 
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rate may change as the polymer degrades. As the polymer begins to lose mass, the 
release rate accelerates because it is determined by a combination of diffusion and 
simultaneous polymer erosion (figure 1) (Heller, 1997, Ahola et al., 1999b, Rich et al., 
2000). The bulk degrading polymers most extensively studied are poly(esters), such as 
copolymers of PLA and PGA.  
 
 
Figure 1. Drug release and biodegradation of aliphatic poly(ester). Drug released by diffusion 
(■), a burst in drug release as the mass loss begins (♦); decrease of molecular weight (∆) and 
mass loss of the polymer (x). 
 
Surface eroding systems (heterogeneous erosion) lose material from the surface and 
the erosion rate is dependent on the surface area and the geometry of the device, i.e. 
the radius to thickness ratio controls the matrix erosion time, rather than the volume of 
the polymer matrix (Tamada and Langer, 1993, Katzhendler et al., 1997, Akbari et al., 
1998). The molecular weight of the polymer generally does not change significantly as 
a function of time (Baker, 1987). Achieving surface erosion, however, requires that 
the degradation rate of the polymer matrix surface be much faster than the rate of 
water penetration into the matrix (Langer, 1990).  
 
Zero order drug release is obtained with surface erosion controlled systems such as 
poly(anhydrides) or poly(orthoesters). The surface eroding system device design is 
made easier due to the fact that release rates can be controlled by changes in system 
thickness and total drug content. Hopfenberg et al (1976) developed a general 
mathematical equation for drug release from surface degrading slabs, spheres and 
infinite cylinders. This model described in equation 4 assumes that the actual erosion 
process is the rate-limiting step and that the drug release occurs from the primary 
surface area of the device without seepage from the matrix. 
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M 

 −−=
∞ 0
011       (4) 
Mt/M∞ is the fractional released amount of drug, C0 is the initial concentration of the 
drug in the matrix, a is the initial radius for a sphere or cylinder, k0 is the zero order 
rate constant for surface erosion and n is the shape factor. A shape factor that was 
defined in the equation by Hopfenberg, has in subsequent studies been applied to other 
geometrical forms, such as squares and half-spheres (Karasulu et al., 2000). According 
to Katzhendler, the erosion rates are different in the radial and axial directions 
(Katzhendler et al., 1997). Drug release from a surface eroding polymer may be 
controlled solely by erosion of the polymer matrix and the release of drug is constant 
provided that the surface area of the matrix and the drug concentration remain 
constant during the drug release period (Langer, 1980). However, the surface area 
decreases as the implant is eroded, with a consequent decrease in the release of drug. 
Consequently, a geometry that does not change its surface area as a function of time is 
required to attain more uniform and zero order release (Park et al., 1993).  
 
 
Figure 2. Drug release and mass loss of polymer from heterogeneously degrading polymer 
(surface erosion). Drug released (■), mass loss of the polymer (∆). 
 
True surface erosion where matrix mass loss is equal to the drug release rate (figure 2) 
is difficult to achieve and often diffusion of the drug molecules may still be rate 
limiting. For highly water-soluble drugs especially, the release rate is controlled 
mainly by diffusion through the matrix, whereas the erosion process controls the 
release rate of low water-soluble drugs. Thus, the release rate may be a combination of 
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erosion control (zero-order) and diffusion control (square root of time kinetics) (Urtti, 
1985).  
 
 
2.2.4. Empirical equation for describing drug release 
 
To simplify the analysis of controlled release data from polymeric devices of varying 
geometry, an empirical, exponential expression was developed to relate the fractional 
release of drug to the release time, (Ritger and Peppas, 1987b, Ritger and Peppas, 
1987a): 
 
nt kt
M
M =
∞
        (5) 
where Mt/M∞ is the fractional solute release, t is the release time, k is a constant and n 
is the exponent characteristic of the release mechanism (Ritger and Peppas, 1987a, 
Ritger and Peppas, 1987b). This equation applies until 60% of the total amount of 
drug is released. It predicts that the fractional release of drug is exponentially related 
to the release time and it adequately describes the release of drug from slabs, spheres, 
cylinders and discs from both swellable and non-swellable matrices (Table 1). The 
slope (n) of the log(drug released) vs. log(time) plot is 0.5 for pure Fickian diffusion. 
An anomalous non-Fickian diffusion pattern (n = 0.5-1 or n = 0.45-0.89) is observed 
when the rates of the solvent penetration and drug release are in the same range. This 
deviation is due to increasing drug diffusivity in the matrix by the solvent induced 
relaxation of the polymers. Zero order drug release (n = 0.89 or n =1) can be achieved 
when drug diffusion is rapid compared to the constant rate of solvent induced 
relaxation and swelling in the polymer (Case II transport for swellable polymers). Use 
of this equation to analyse data of drug release from a porous system will probably 
lead to n < 0.5, since the combined mechanisms  (diffusion through the matrix and 
partially through water-filled pores) will shift the release exponent toward smaller 
values (Peppas, 1985). Figure 3 describes the effect of exponent n on the release 
profile from controlled release systems. 
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Table 1. Diffusional exponent and mechanism of diffusional release from cylindrical 
and spherical non-swellable and swellable controlled release systems (Peppas, 1985, 
Ritger and Peppas, 1987b, Ritger and Peppas, 1987a). 
Controlled release 
system 
Diffusional exponent 
n 
Drug release mechanism 
Non-swellable < 0.5 Release from porous 
material 
 0.5 Fickian diffusion 
 0.5-1.0 Anomalous (non-Fickian) 
transport 
 1.0 Zero-order release 
Swellable 0.45 Fickian diffusion 
 0.45-0.89 Anomalous (non-Fickian) 
transport 
 0.89 Case-II transport 
 >1 Super-Case II transport 
 
 
Figure 3. Fractional drug release versus time curves with different values of exponent n (0.25-
1.5) when the constant (k) in the equation (5) is  0.6. 
 
 
2.3. SOL-GEL TECHNOLOGY 
 
Sol-gel produced oxides are used in numerous applications, such as coatings and thin 
films in electronic or optical components and devices. In addition, sol-gel monoliths 
and coatings have been investigated as matrices for catalysts, optical filters or as 
biosensors in diagnostic applications (Braun et al., 1990, Lev, 1992, Lev et al., 1995). 
The process has been used to produce amorphous materials in various forms, 
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including powders, fibers, coatings and thin films, monoliths and porous membranes 
(Böttcher et al., 1999, Ahola et al., 2000, Peltola et al., 2001). Sol-gel processing 
offers advantages such as low processing temperature and high homogeneity and 
purity of the material enabling preparation of hybrid materials and incorporation of 
drug substances or even cells (Pope, 1995, Baker et al. 1999). A large number of 
proteins (trypsin, glucose oxidase and hydrogen peroxidase), that retain their activity 
and stay in the matrix, have been incorporated into silica xerogel matrix through 
moulding.  
 
The sol-gel process involves the manufacture of inorganic matrices through the 
formation of a colloidal suspension (sol) and the gelation of the sol to form a wet gel, 
which, after spontaneous drying, forms dry gel called xerogel. Most sol-gel techniques 
use water and low molecular weight alkoxysilanes, such as tetraethoxysilane (TEOS) 
or tetramethoxysilane (TMOS), as silica precursors. The alkoxide hydrolyses with 
water forming silanols, with either acid or base as catalyst (Brinker and Scherer, 
1990). The reactions of alkoxysilanes can be summarised in terms of three steps: 
hydrolysis of the alkoxide, silanol-silanol condensation, and silanol-ester condensation 
(Figure 4). Hydrolysis occurs by the nucleophilic attack of the oxygen contained in 
water in the silicon atom. Subsequent condensation reactions take place producing 
siloxane bonds. The polymerisation stages may be described as, i) polymerisation of 
monomers to polymers, ii) condensation of polymers to primary crystals, iii) growth or 
agglomeration of primary crystals to particles and iv) linking of particles into chains 
and to three dimensional network (figure 4) (Iler, 1979, Brinker and Scherer, 1990). 
Networks of the chains extend throughout the liquid medium, thickening the network 
into a gel. In the last stage water and alcohol are evacuated from the network structure 
causing gradual shrinkage and even cracking of the monolithic gel.  
 
 
 
 
 
Hydrolysis reaction 
≡ Si-OR + H2O  →   ≡ Si-OH + ROH 
 
Alcohol condensation 
≡ Si-OH + RO-Si → Si-O-Si ≡ + ROH 
 
Water condensation 
≡ Si-OH + HO-Si → Si-O-Si ≡ + H2O 
 
 
 
 
Figure 4. Reactions of alkoxysilanes (Brinker and Scherer, 1990) and polymerisation behaviour 
of silica. After Iler by Jokinen (Iler, 1979, Jokinen et al., 1998) 
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2.3.1. Factors affecting the structure of sol-gel processed silica xerogel 
 
A porous and amorphous structure is one of the most characteristic features of sol-gel 
derived silica xerogel. Reactivity of the matrix, due to free hydroxyl groups, is the 
other typical property of silica xerogel. The microstructure of silica xerogel can be 
controlled by changing the water/alkoxide molar ratio, the catalyst type or 
concentration, by consolidating /sintering the silica xerogel by heat treatment or by 
using alkyl-substituted alkoxides or other additives.  
 
2.3.1.1. Water/alkoxide molar ratio  
The water/alkoxide molar ratio (r) has significant effect on the silica xerogel 
microstructure (Brinker and Scherer, 1990). When the water/alkoxide molar ratio is 
low, alcohol condensation is dominating and gelation time is longer, leading to more 
microporous materials. Gels made from higher water content sol (r > 4) have shown 
more coarse microstructure than gels made from lower water content sols (r < 4) (Ro 
and Chung, 1991). However, when the water/alkoxide ratio is more than 10, the 
microstructure was only slightly dependent on water content. The gels made from 
lower water content sols have more unreacted alkoxy ligands than those from higher 
water content sol and therefore form more linear chain-like structures (Kusakabe et al., 
1999). At higher water concentration, more branched polymers are formed. Fiber 
drawing is possible from sols made at low water/TEOS ratio and low pH (Lev et al., 
1995). 
 
2.3.1.2. Catalyst 
The effect of pH on the pore structure and morphology has been extensively studied 
(Brinker and Scherer, 1990). Changes in solution pH alter the relative rates of 
hydrolysis and condensation, yielding products ranging from weakly branched to 
particulate silica sols (Brinker and Scherer, 1990). Iler divides the polymerisation 
process into three approximate pH domains: pH < 2, pH 2-7 and pH > 7 (Iler, 1979). 
pH = 7 appears as a boundary because the silica solubility and dissolution rates are 
maximised at or above pH = 7. The kinetics and growth mechanisms of the reaction 
depend on the pH value of the solution. With acidic pH, particle growth stops once the 
size of 2 to 4 nm is reached. Above pH = 7 particle growth is mainly dependent on the 
temperature and particles of more than 100 nm in diameter can be formed (particulate 
sols). Above pH = 7 particles are negatively charged and they repel each other and no 
aggregation of particles occurs (particulate sols). At low pH, near the IEP, repulsive 
forces between particles are low and particles collide and form continuous networks 
leading to gels (gel networks)(figure 4). 
 
The relative rates of hydrolysis and condensation effectively determine the 
morphology of the final xerogel. Generally, silica particles are positively charged at 
low pH and negatively charged at high pH. At the isoelectric point of silica (IEP, 
between pH=1 and pH=3), where the electrophoretic mobility of particles is zero, or at 
the point of the zero charge, where the surface charge is zero the condensation rate is 
slowest (Iler, 1979, Brinker and Scherer, 1990). Weakly basic to moderate acidic sols 
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have significant amounts of deprotonated silanol groups (SiO-) which increase the 
condensation rate causing a formation of highly branched silica species. Gelation of 
these branched species results in the formation of mesoporous regions with a pore size 
between 2 nm and 50 nm. As the pH is lowered to the isoelectric point (between 1 to 
3), the gelation times are increased and this leads to linear or randomly branched silica 
gel having highly microporous structure with the pore diameter < 2 nm (Meixner and 
Dyer, 1999). At very high acid concentrations, below isoelectric point (below 1) the 
dried xerogels become more mesoporous (Curran and Stiegman, 1999). This is due to 
the protonation of silanols to produce (SiOH2+) groups, which are good leaving groups 
and act to increase the rate of condensation (Brinker and Scherer, 1990).  
 
2.3.1.3. Organic-inorganic composite materials 
Organically modified silicates represent hybrid systems in which several precursor 
types are combined. They are intermediate between glasses and polymers. Silica 
xerogels where organic chains are covalently attached to the silica atom of the 
network are called type II compounds (Baker et al., 1999). Organic groups linked to 
the oxide network by stable chemical bonds change the inner structure by reducing the 
degree of cross-linking. The amount of surface silanol groups decreases and leads to 
modified chemical reactivity and enhanced hydrophobicity (Schmidt, 1989, Lev et al., 
1995, Mah and Chung, 1995). By adjusting the ratio of tetra alkoxysilane and alkyl 
substituted alkoxide, the structure and hydrophobicity of the silica gel can be 
controlled. The pore size and the specific surface area of the silica xerogel matrix 
increases with increasing length of the alkyl-group (Kusakabe et al., 1999). The 
presence of mesopores is more significant in silica gels with longer alkyl-chains. 
These changes in the structure of silica gel also influence the release rate of drug 
substances (Unger et al., 1983, Böttcher et al., 1998, Ahola et al., 2001).  
 
Type I compounds have organic agents, like surfactants or inorganic salts, proteins or 
charged polymers attached with van der Waals or hydrophobic interactions within the 
silica xerogel network (Sanchez and Ribot, 1994). The presence of these agents 
controls the pore size and the specific surface area of the silica gel (Sato et al., 1990, 
Murakata et al., 1992, Vong et al., 1997). Polyethylene glycol affects the formation of 
silica particles at the colloidal level during polycondensation by forming hydrogen 
bonds with residual silanol groups in the silica network (Jokinen et al., 1998). It only 
affects the amount of micropores and the mean pore size of calcined silica xerogel 
increases (Sato et al., 1990). Organic compounds may also serve as templates to 
control the pore size and are added to the initial sol, as in the production of 
mesoporous silica (Kresge et al., 1992, Lindén et al., 1998, Vallet-Regi et al., 2001).  
 
2.3.2. Sol-gel derived silica xerogels in drug delivery 
 
Sol-gel derived silica xerogel has also been studied as a carrier material for various 
drugs, peptides and proteins (Sieminska and Zerda, 1996, Nicoll et al., 1997, Böttcher 
et al., 1998, Falaize et al., 1999, Santos et al., 1999, Ahola et al., 2000, Ahola et al., 
2001). Bioactive agents can be incorporated into silica xerogel either by adsorbing 
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drug onto the surface of the heat-treated silica xerogel (Sieminska et al., 1997, Ahola 
et al., 1999a, Otsuka et al., 2000) or by adding the drug during the sol-gel 
manufacturing process (Unger et al., 1983, Nicoll et al., 1997 Böttcher et al., 1998, 
Ahola et al., 2000, Ahola et al., 2001). The solubility of drugs may limit the amount of 
drug added during the sol-gel phase (Sieminska and Zerda, 1996).  
 
Incorporation of drug substances into sol-gel derived silica sol was introduced as early 
as 1983 (Unger et al., 1983). Unger found that the physicochemical characteristics of 
the drug molecule significantly control the release rate. Basic drugs are released in a 
controlled manner, whereas neutral or acidic drugs are released very quickly. This is 
due to the ionic properties of silica xerogel structure. Drug molecules with reactive 
functional groups, such as alcoholic or phenolic OH-groups can be chemically linked 
to silica surface by ≡Si-O-C≡ bonds (Eckert-Lill et al., 1987) or by hydrogen bonds 
(Sieminska and Zerda, 1996). The amount of hydroxyl and carbonyl groups in a drug 
molecule affects the bonding and release rate of the drug. Stronger hydrogen bonds are 
formed with weak nitrogen bases, like pyridine, than with oxygen atoms of the ether 
or keto groups (Iler, 1979). Hydrogen bonds are formed between pH 1.5 to 3.0. 
Compounds that contain cationic groups combine with silica at all pH values and the 
bonds may involve both ionic bonding and hydrogen bonding. However, at a low pH 
below 3 to 4 interactions involve only hydrogen bonding. In addition large 
hydrophobic moieties intensify the adsorption to the silica surface (Iler, 1979). In 
some cases hydrophobic drug molecules, like hydrocortisone, may be permanently 
trapped within silica xerogel (Sieminska and Zerda, 1996, Otsuka et al., 2000). They 
are probably trapped to inter-particle volume (Otsuka et al., 2000).  
 
The drug release rate from a silica xerogel matrix can be controlled by adding water 
soluble polymers such as polyethylene glycol or sorbitol or by substituting alkoxide 
with covalently linked organomodified alkoxide during synthesis (Unger et al., 1983, 
Böttcher et al., 1997, Böttcher et al., 1998, Ahola et al., 2001). The surface of silica 
gel can also be modified by using silane-coupling agents to improve the surface 
affinity and drug release rate of very hydrophobic drugs (Otsuka et al., 2000). In 
addition, the drug release rate can be controlled by adjusting the degree of drying or 
the particle size (Nicoll et al., 1997, Ahola et al., 2001). The effect of pore size, which 
can be modified by water/alkoxide ratio, on the release rate of drugs is also obvious 
(Sieminska and Zerda, 1996, Aughenbaugh et al., 2001). Crushed silica xerogel 
containing incorporated drug molecules have also been mixed with polyester 
copolymers in order to control the release of the drug (Ahola et al., 1999b, Rich et al., 
2000). 
 
The release mechanisms of drugs from a silica xerogel matrix are not extensively 
evaluated. The release of nifedipine from crushed silica xerogel particles is assumed to 
occur through solvent filled capillary channels and to obey square root of time kinetics 
(Böttcher et al., 1998). In addition, progesterone diffused from the porous silica 
xerogel obeys Fick`s second law equation (Sieminska and Zerda, 1996). The release 
rate is governed by the rates of dissolution and diffusion. The release of toremifene is 
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also diffusion controlled from crushed particles but conforms to zero order kinetics 
from monoliths (Ahola et al., 1999a, 2000). In addition, the release of heparin from 
silica xerogel rods obeys zero order release kinetics (Ahola et al., 2001). The release 
mechanism of oily drugs, such as phytonadione, proceeds in two phases, a rapid 
release phase, not due to interaction with the silica surface and a slower drug release 
due to interaction (Otsuka et al., 2000). 
 
2.3.3. Biocompatibility of silica based glasses  
 
Biomaterials are expected to perform without any adverse effects, such as toxic, 
carcinogenic immunogenic and inflammatory responses. Biocompatibility of the 
material is defined as the appropriate effects, either local or systemic, of a biomaterial 
on a host (Williams, 1988). The biocompatibility of biomaterials is often described in 
terms of the acute and chronic inflammatory response and as the fibrous capsule seen 
at various time intervals after implantation of the material. Events following 
implantation of foreign material are injury, acute inflammation, chronic inflammation, 
granulation tissue, foreign body formation and fibrosis. Neutrophils predominate 
during the first several days and are replaced by monocytes. The acute inflammation 
lasts up to a few days, depending on the extent of the injury. Chronic inflammation is 
characterised by the presence of macrophages, monocytes and lymphocytes with the 
proliferation of blood vessels and connective tissue. The end stage of the healing 
response to biomaterials is generally fibrous encapsulation and has been considered as 
a sign of biocompatibility of the material. However, the fibrous capsule surrounding 
the implant may affect the drug release and absorption into the circulation. (Anderson 
et al., 1981, Anderson, 1994, Tang and Eaton, 1995, Park and Park, 1996, Andersson 
and Langone, 1999). 
 
Silicon has been recognised as an essential trace element in the body and to participate 
in connective tissue, especially cartilage and bone formation (Carlisle, 1986). 
Crystalline silicon dioxide is known as a cytotoxic agent in macrophages and is known 
to cause enhanced formation of granulation tissue (Allison et al., 1966, Absher et al., 
1989). Sol-gel derived glasses, on the other hand, are biocompatible and also 
bioactive, i.e. they form a chemical bond with living tissue and promote bone 
formation (Hench and Wilson, 1986, Li et al., 1992, Klein et al., 1995). 
Subcutaneously implanted pure silica xerogel as well as bioactive glass are surrounded 
by collagen fibres containing only few inflammatory cells after 4 weeks (Hench and 
Wilson, 1986, Radin et al., 1998, Kortesuo et al., 1999). Wilson and co-workers 
conducted a series of both in vitro and in vivo tests to evaluate the toxicity of glasses 
containing silica (Wilson et al., 1981). All tests showed silica-containing glass to be 
non-toxic and biocompatible. The proliferation of cultured murine fibroblasts and the 
activation of human polymorphonuclear leukocytes by sol-gel derived glasses has also 
been studied. Sol-gel glass neither caused the inhibition of fibroblast growth nor 
induced a significant inflammatory response by polymorphonuclear leukocytes 
(Wilson et al., 1981, Palumbo et al., 1997). Therefore sol-gel-derived glass is 
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considered a non-toxic material, due to its ability to induce normal growth of various 
cells.  
 
2.3.4. Elimination of silica based material 
 
When silica xerogel is exposed to water it starts to degrade through hydrolysis of the 
siloxane bonds to Si(OH)4 (Brinker and Scherer, 1990), which diffuses into the local 
tissue around the implant, enters the bloodstream or lymphic circulation and is 
excreted in the urine through the kidneys or is actively phagocytised by the 
macrophages (Lai et al., 1998). During the resorption the Si concentration remains 
within the physiological range and no accumulation of silica was found in peripheral 
organs. In other words silica is harmlessly excreted in a soluble form through the 
kidneys. 
 
 
2.4. CHARACTERISATION OF DEXMEDETOMIDINE AND 
TOREMIFENE 
 
2.4.1. Physico-chemical characteristics of the drug 
 
Dexmedetomidine, d-4-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole (figure 5), is a 
very specific, even full agonist at several alpha 2-adrenergic receptor sites (Aantaa et 
al., 1993). It is the highly receptor selective dextro enantiomer of medetomidine 
(Savola and Virtanen, 1991). The molecular weight of hydrochloride salt is 236.7 
(Rajala et al., 1994). It is weakly basic with a pKa value of about 7.1 and lipophilic 
with the logP about 2.8 at pH=7.4 with octanol as an organic solvent (Savola et al., 
1986).  
 
Figure 5. Structure of dexmedetomidine and toremifene 
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Toremifene, (Z)-4-chloro-1,2-diphenyl-1-[4-(2-(N,N-dimethylamino)ethoxy] phenyl]-
1-butene (figure 5), is a selective estrogen receptor modulator for treatment of 
metastatic breast cancer. Toremifene is weakly basic with the pKa 8.0 and lipophilic 
having the logP value about 3.4 at pH 7.4 with octanol as an organic solvent. The 
molecular weight of citrate salt is 598.  
 
2.4.2. Basic pharmacokinetics of dexmedetomidine and toremifene 
 
Dexmedetomidine is used as intramuscular injection or as a slow intravenous infusion, 
because rapid intravenous injection due to transient peak concentration values during 
the distribution phase, causes vasoconstriction (Scheinin et al., 1989). The 
pharmacokinetics of dexmedetomidine in men is best described by a three-
compartment model after intravenous administration (Dyck et al., 1993a, Dyck et al., 
1993b). The effect of racemic medetomidine is dose dependent at the dose range 10-
80 ug/kg for dogs. At higher doses the strength of sedation does not increase, only the 
duration of the effect (Vainio, 1989). The estimated LD50 value for dexmedetomidine 
in dogs is 2000 µg/kg.  
 
Dexmedetomidine is rapidly absorbed after i.m. injection. Time to maximum 
concentration after i.m. injection in men was 1.6 to 1.7 hours (Scheinin et al., 1992). 
Peak concentration was achieved within 0.5 h after i.m. injection in dogs (Salonen, 
1989). Dexmedetomidine distributes into tissue including the brain. The mean 
distribution half-life is less than 10 minutes in dogs after i.v. injection (Salonen, 
1989). The apparent volume of distribution is about 2.8 l/kg in dogs (i.v.) (Salonen, 
1989) and 2.1 to 2.6 l/kg in men (Scheinin et al., 1992). The elimination half-life is 1.6 
to 2.4 h after i.m. administration in men (Scheinin et al., 1992). Elimination from 
serum occurs with a half-life of 0.97 to 1.6 h in dogs (Kuusela et al., 2000). Most 
(85%) of the racemic medetomidine is present in protein bound form (Salonen, 1989).  
 
Racemic medetomidine is metabolised in the liver and the metabolites are excreted in 
the urine. Unchanged medetomidine represented about 1-10 % of the urinary excretion 
products (Salonen and Eloranta, 1990). The primary hepatic metabolic route of 
medetomidine is hydroxylation of the methyl substituent at the aromatic ring. 
Hydroxymedetomidine is further metabolised either into O-glucuronide or to 
carboxylic acid conjugate (Salonen and Eloranta, 1990). The first pass metabolism in 
the liver is extensive and pharmacological effects are achieved at very high doses 
(Vainio, 1989). The metabolisms of medetomidine and dexmedetomidine differ in 
their respective rates of hydroxylation. The P450 isozyme has a higher affinity to 
dexmedetomidine, causing higher rates of oxidation (Salonen and Eloranta, 1990). 
 
Toremifene is completely absorbed from the gastrointestinal tract without a first-pass 
metabolism. More than 99% is bound to plasma proteins (Sipilä et al., 1988). The 
kinetics are linear in the range of 10-680 mg (Anttila et al., 1990). Peak concentration 
in the serum after oral administration is achieved after 4  hours (Anttila et al., 1990).  
The apparent volume of distribution is 11.8 l/kg after oral administration (Anttila et 
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al., 1995). The mean half-life of distribution after oral administration is 4 hours. The 
elimination is slow with a mean half-life of 5 days (Anttila et al., 1990). The 
consequence of the long elimination half-life, is that a significant accumulation of the 
drug occurs during repeated administration. The steady state level is achieved within 6 
weeks after the start of peroral therapy (Anttila et al., 1990). 
 
Toremifene is metabolised in the liver by cytochrome P450 (Berthou et al., 1994). 
More than ten metabolites have been identified, the main metabolite being N-
demethyltoremifene, that show antitumor activity (Anttila et al., 1990, Coradoni et al., 
1991). 
 
2.4.3. Clinical applications of dexmedetomidine and toremifene 
 
Alpha 2-agonists are widely used as a sedative, analgesic and anaesthetic 
premedication. Dexmedetomidine (Precedex®) is commercially available for sedation 
of patients in intensive care. Dexmedetomidine is well tolerated and the most 
frequently observed adverse effects are hypotension and bradycardia, which, however, 
are quite easily controlled. The effect is achieved with im, iv and sc modes of 
injection. The racemic mixture, medetomidine (Domitor®), which also includes the 
pharmacologically inactive l-isomer, has been approved for veterinary use in several 
countries. 
 
Toremifene (Fareston ®) is a triphenylethylene antiestrogen, which acts as 
competitive antagonist at the estrogen receptor (Kangas, 1990) and is used in 
hormonal therapy as an anticancer drug for the treatment of metastatic breast cancer 
(Valavaara, 1990). 
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3. AIMS OF THE STUDY 
 
The main objective of this study was to evaluate sol-gel based silica gel as an 
implantable  or injectable biodegradable carrier for controlled drug delivery. The 
effect of various synthesis parameters and manufacturing methods, casting and spray 
drying on the release rate of model drugs was studied in vitro. Two model drugs 
(toremifene citrate and dexmedetomidine hydrochloride), both basic drugs but with 
different physicochemical and pharmacokinetic properties, were incorporated into 
silica gel during the synthesis phase. In vivo release of toremifene from a silica 
xerogel monolith and degradation of the matrix was studied in mice. Bioavailability of 
dexmedetomidine from implanted silica xerogel monoliths or injected silica gel 
microparticles was estimated from the pharmacokinetic data in dogs. 
 
The specific aims of this study were: 
1. To confirm biodegradation and evaluate tissue effects of the sol-gel derived silica 
xerogel carrier material at the implantation site and in the specific organs in mice  
 
2. To study the effects of manufacturing methods (spray drying, casting method) on 
the release behaviour of dexmedetomdine and toremifene and degradation of the 
matrix in vitro 
 
3. To study effects of sol-gel synthesis parameters (pH of the sol, water/TEOS ratio 
and partial substitution of silica precursor with alkyl-substituted alkoxide) on the 
release behaviour of dexmedetomidine and degradation of the matrix in vitro 
 
4. To investigate in vivo whether an implantable or injectable controlled release 
formulation for toremifene citrate and dexmedetomidine hydrochloride could be 
developed.  
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4. MATERIALS AND METHODS 
 
4.1. MODEL DRUGS 
 
Dexmedetomidine hydrochloride (II-V) and toremifene citrate (I-II) were synthesised 
at Orion Corporation (Espoo, Finland). Physicochemical characteristics of drugs are 
described in section 2.4.1. 3H-toremifene was synthesised as described earlier (Kangas 
et al., 1989). The specific activity of the material was 16 Ci/mmol (I). 
 
 
4.2. PREPARATION OF SOL-GEL PROCESSED SILICA GEL 
MONOLITHS AND MICROPARTICLES  
 
Silica sols were prepared at room temperature by acid hydrolysis of TEOS or TEOS 
co-hydrolysed with alkyl-substituted alkoxides and deionised water (I – V). 
Toremifene citrate or dexmedetomidine HCl were dissolved into hydrolysed sol.  
Silica xerogel monoliths containing 3H-toremifene/toremifene citrate for implantation 
study in mice were prepared by dissolving 33 mg/g of toremifene citrate in the silica 
sol (I).  3H-toremifene was added to the silica sol to produce a final radioactivity of 16 
µCi/g. 
 
The drug concentration in monoliths and microparticles was calculated as a theoretical 
concentration by assuming that all of the drug dissolved in the silica sol was 
incorporated into the silica gel structure (I-V). The actual concentration of drug could 
not be determined because silica gel dissolves at reasonable speed only at a very high 
pH (> 10) (Brinker and Scherer, 1990). 
 
4.2.1. Monoliths 
 
Hydrolysed silica sol was cast into Teflon moulds (rod or disc shaped) that were 
tightly closed and kept at 40°C and 40% relative humidity for polycondensation and 
gelation. After gelation the silica gel monoliths were dried to a constant weight at 
40°C and 40% relative humidity (I, III, IV, V).  
 
4.2.2. Microparticles 
 
Hydrolysed silica sol was spray dried with a mini spray dryer (B-191, Büchi 
Labortechnik AG; Switzerland). Spray drying process parameters were: inlet air 
temperature 135°C, pump 16 (dialling setting), aspirator 95 (dialling setting) and 
spray-flow 600 Nl/h. A 0.77 mm nozzle was used throughout the experiments (II, IV, 
V).  
 
Volumetric particle size and size distribution of the microparticles was obtained by 
laser diffractometry using Sympatec/Helos laser diffraction equipment (Sympatec 
GmbH, Germany). The samples were dispersed in water and treated with ultrasound 
equipment for 5 seconds to ensure a homogenous dispersion. The measurements were 
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carried out using a 50-mm or 100-mm lens. The results are the average of five 
withdrawals (II, IV, V). 
 
The shape and surface morphology of the microparticles was determined from 
micrographs taken with scanning electron microscope (SEM-EDX Stereoscan 360, 
Cambridge Instruments, UK) (II, IV, V). 
 
The yield of microparticles was calculated from the theoretical amount silica gel 
(SiO2). The yield varied between 42.8 and 77.7 % for silica gel microparticles 
containing toremifene citrate and between 20.6 and 49.2 % for microparticles 
containing dexmedetomidine HCl (II). 
 
 
4.3. THE SOL-GEL SYNTHESIS PARAMETERS STUDIED IN THE 
PROCESSING OF  SILICA GEL MONOLITHS AND 
MICROPARTICLES 
 
4.3.1. pH of the sol 
 
The hydrolysis and condensation reactions were catalysed in two different ways, one-
step acid catalysis with various concentrations of HCl and CH3COOH or two-step 
catalysis with HCl and NH3 in order to get silica gel monoliths or microparticles 
manufactured at pH 1; 2.3; 3 and 5 at water/TEOS ratio 14 (III, table 1; V, table 1). 
 
4.3.2. Water/TEOS ratio 
 
Silica monoliths were manufactured at water/TEOS ratios 6, 14 and 28 (III, table 1) 
and microparticles at ratios 6, 10, 14, 28 and 35 at pH = 2.3 (V, table 1).  
 
4.3.3. Alkyl-substituted silica xerogel 
 
Alkyl-substituted silica gels were prepared at pH = 2.3 with a water/TEOS ratio of 14 
using HCl as catalyst. Partial substitution of silica sol was carried out by co-hydrolysis 
of TEOS with 5, 10 or 25 mol-% of DMDES, METES or ETES (IV). 
 
4.3.4. Size and shape of the monoliths 
 
The influence of silica xerogel monolith size on the release rate of dexmedetomidine 
was studied with rod-shaped monoliths with a length of 11.5 mm and diameters of 1.9 
mm, 1.4 mm and 0.95 mm and with disc-shaped monoliths with a diameter of 4.6 mm 
and a thickness of 1.59 mm prepared at pH = 3 with a water/TEOS ratio of 14 having 
1 wt-% of dexmedetomidine HCl  in the sol (III).  
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4.3.5. Drug concentration 
 
Toremifene citrate was added to silica sol with a concentration of 0.5, 1.0, 2.0, 2.5 and 
3.0 wt-% and the sol was spray dried to microparticles (II). The concentration of 
dexmedetomidine HCl varied between 0.5 and 2 wt-% in silica sol (II, III, IV).  
 
 
4.4. DRUG RELEASE AND MATRIX DEGRADATION STUDIES IN 
VITRO 
 
The release of toremifene and dexmedetomidine from silica gel monoliths and 
microparticles was performed in a dissolution apparatus II (U.S.P 24) at 37°C with a 
rotation speed of 50 rpm using 250 ml of either 0.5% SDS/SBF- buffer (pH 7.4) (I-IV) 
or 0.9% NaCl as dissolution medium (V). Toremifene and dexmedetomidine were 
analysed with an UV-spectrophotometer at the maximum absorbance of the drug. 
 
Simultaneously with the drug release studies, the degradation of the silica gel 
monoliths and microparticles was determined. Dissolved silicon was determined as 
Si(OH)4 as a molybdenum blue complex at 820 nm (Koch and Koch-Dedic, 1974) (I-
V). 
 
 
4.5. IN VIVO STUDIES 
 
All animal experiments were approved by the animal care committee of Orion 
Corporation. 
 
4.5.1. Tissue effects and release of toremifene from silica xerogel implants in 
mice  
 
Thirty female mice (C57Bl, Denmark) with an average weight of 19.6 g (SD 1.2) 
received implants subcutaneously on the back on either side of the backbone with 3H-
toremifene loaded silica implants (a total of 2 implants were placed in each mouse) 
and thirty mice with untreated silica implants. The 3H-toremifene dose was about 80 
µCi/kg (0.8 µCi/implant), toremifene citrate 350 mg/kg (app. 3.4 mg/implant) and 
silica xerogel about 1.53 g/kg body weight. The silica xerogel implants were round 
with a diameter of approximately 4.7 mm and a thickness of 0.9 mm (I). 
 
The animals were sacrificed at 7, 14, 21, 28, 35 and 42 days (5 mice per time period) 
after implantation. The silica xerogel implants on the left side of the backbone were 
removed together with surrounding tissue and fixed in 70% ethanol and embedded in 
PMMA (Technovit). Sections of 20 µm were stained with toluidine blue. Samples of 
liver, kidney, mesenterial lymph node and uterus were fixed in buffered formaldehyde 
and embedded in paraffin. Sections of 6 µm were stained with hematoxylin eosin. The 
samples were evaluated using light microscopy. The samples of the implantation site 
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were studied from all interim kills, but liver, kidney, lymph node and uterus only from 
the animals treated 7, 28 and 42 days (I). 
 
The percentage of implant remaining at each time point was calculated. To determine 
the amount of toremifene remaining in the implants, the dried implants were dissolved 
in 0.1 N NaOH solution and the activity was measured in liquid scintillation counter 
(I).  
 
4.5.2. Bioavailability of dexmedetomidine in dogs  
 
Formulations. Silica gel formulations administered to dogs are described in table 1. As 
a reference dexmedetomidine HCl dissolved in 0.9% NaCl (10 and 20 µg/ml) was 
administered subcutaneously (5 ml) with a dose of 0.05 or 0.1 mg. The test 
formulations were rod-shaped silica gel monoliths prepared by the casting method or 
microparticles prepared by spray drying. The monoliths were prepared from a sol, 
where 25 mol-% of TEOS was substituted by alkyl-substituted alkoxide, 
dimethyl(diethoxy)silane (DMDES) at pH = 2.3 with a water/TEOS ratio of 14. The 
amount of dexmedetomidine HCl dissolved in the sol was either 1 wt-% or 2 wt-% 
corresponding respectively to 7.7 wt-% and 15.4 wt-% in dry gel (IV). The spray-dried 
microparticles were processed from a sol synthesised at pH = 2.3 with a water/TEOS 
ratio of 14 containing 1 wt-% dexmedetomidine HCl in the sol (V). 
 
Table 1. Dexmedetomidine HCl containing silica gel microparticles (prepared at pH = 
2.3, water/TEOS ratio 14), monoliths (25 mol-% DMDES/75 mol-% TEOS, pH = 2.3, 
water/TEOS 14) and reference doses used in bioavailability studies in dogs. 
Treatment Dexmedetomidine HCl 
dose range, µg/kg
Dogs (n), 
weight of dogs
0.05 mg of dexmedetomidine HCl in 5 
ml of 0.9% NaCl (IV) 
4.8 – 6.1 n = 4 
8.2 – 10.4 kg 
0.1 mg of dexmedetomidine HCl in 5 
ml of 0.9% NaCl (V) 
9.5 – 12.0 n = 4 
8.3 – 10.5 kg
60 mg of silica gel microparticles 
containing 4.6 mg of dexmedetomidine 
HCl in 5 ml of 0.9% NaCl (V) 
460– 540 n = 3 
8.6 - 10.1 kg
Two silica gel monoliths (53.9 mg ± 
0.8) containing 4.15 mg (± 0.007) of 
dexmedetomidine HCl (IV) 
420 – 440 n = 3 
9.1 – 9.8 kg*
Two silica gel monoliths (57.8 mg ± 
0.3) containing 8.9 mg (± 0.04) of 
dexmedetomidine HCl (IV) 
910 -  980 n = 4 
9.5 – 9.9 kg*
* Typing mistake in original paper IV. 
 
Bioavailability study. Three beagle dogs, two males and one female were 
subcutaneously given 60 mg of silica gel microparticles containing 4.6 mg of 
dexmedetomidine HCl suspended in 5 ml of 0.9 % NaCl solution per dog (V). The 
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amount of dexmedetomidine given varied between 0.46 to 0.54 mg/kg (table 1). Four 
dogs, two males and two females were subcutaneously given two silica gel monoliths 
(total weight 53.9 mg) containing a total of 4.15 mg of dexmedetomidine HCl per dog 
corresponding to 0.42 – 0.44 mg/kg (IV). Three dogs, two male and one female, were 
given two silica gel monoliths (57.8 mg) containing 8.9 mg of dexmedetomidine HCl 
per dog corresponding to 0.91 – 0.98 mg/kg (IV). As a reference, either 0.05 mg (IV) 
or 0.1 mg (V) of dexmedetomidine HCl (in 5 ml of 0.9% NaCl) was given 
subcutaneously each to four dogs, three males and one female in each group. The 
amount of dexmedetomidine given varied between 4.8 – 6.1 and 9.5 – 12.0 µg/kg 
respectively (table 1). 
 
The blood samples for dexmedetomidine serum concentration determination were 
taken from the jugular vein at the predose and 0.5, 1, 2, 4, 6, 8, 24 and 48 hour time 
points.    
 
Assay methods. The dexmedetomidine concentrations in serum were determined by a 
specific and sensitive gas chromatographic mass spectrometric (GC-MS) method, a 
modification of the published method (Vuorilehto et al., 1989). The method is linear 
from 50 pg/ml to 2500 pg/ml for dexmedetomidine (IV, V). 
 
Determination of bioavailability. The pharmacokinetic parameters were calculated by 
non-compartmental analysis using the commercially available software package 
WinNonlin Professional, version 3.0 (Pharsight Corporation, Mountain View, CA, 
USA). The kinetic parameters were derived from the individual dexmedetomidine 
concentration time curves and included: Cmax (the maximum observed 
dexmedetomidine concentration in serum), tmax (the time of occurrence of Cmax) and 
AUC0-48h or AUC0-8h (the area under the concentration versus time curves from time 
zero to either 48 hours or 8 hours using the linear trapezoidal rule) (Gibaldi and 
Perrier, 1982). After the s.c. dosing of reference compound, the last quantifiable 
concentration was reached before eight hours and the area beyond that point was 
approximated using a triangular area up to the next sampling point, the concentration 
of which was deemed to be zero. The individual AUC values were averaged and the 
mean dose normalised values were used to calculate the relative bioavailability of 
dexmedetomidine from silica xerogel. The relative bioavailability of the silica gel test 
formulations was calculated  by comparing the AUC values with the AUC values of 
the reference dose used in the study (IV, V). 
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5. RESULTS 
 
5.1. THE EFFECT OF SYNTHESIS PARAMETERS AND 
MANUFACTURING METHOD ON THE RELEASE RATE OF 
DRUGS AND DEGRADATION OF THE SILICA GEL IN VITRO 
 
5.1.1. Size and shape of silica gel monolith  
 
The effect of device size on the release rate of dexmedetomidine was studied in rod-
shaped monoliths with various diameters or in disc-shaped monoliths (III, fig 4a). The 
burst release of dexmedetomidine was about 40% from rod-shaped monoliths with a 
diameter of 0.95 mm, whereas it was less than 20% from disc-shaped monoliths with a 
diameter of 4.6 mm and rod-shaped monoliths with diameter of 1.4 mm and 1.9 mm. 
After 30-hours of dissolution, more or less 100 % was released from 0.9-mm rod-
shaped monoliths, 80% from 1.4-mm monoliths and 70% from 1.9-mm monoliths. 
From disc-shaped monoliths dexmedetomidine release was initially as fast as from the 
rods for the first six hours. Later the release rate slowed down and about 54% was 
released after 30 hours.  
 
The amount of silica xerogel degraded after 30-hours of dissolution was at least 15% 
for a disc-shaped monolith (diameter 4.6 mm) and at most 28% for a rod-shaped 
monolith with a 0.95 mm diameter (III, fig 4 b). Rod-shaped monoliths with diameters 
of 1.9 mm and 1.4 mm as well as disc-shaped monoliths had a lag phase before the 
degradation of the silica xerogel matrix began. 
 
5.1.2. pH and water/TEOS ratio  
 
Monoliths. The sols with pH = 2.3 (hydrochloric acid as catalyst) and pH = 3 (acetic 
acid as catalyst) were synthesised near the isoelectric point of silica, which generally 
is dependent on the acid used as a catalyst (Brinker and Scherer, 1990). The release of 
dexmedetomidine was faster from acetic acid catalysed silica gel (pH = 3) than from 
hydrochloric acid catalysed silica gel prepared at pH = 2.3 with a water/TEOS ratio of 
14 (III, fig 1). The amount of dexmedetomidine released varied between 44 % (pH = 
2.3) and 92 % (pH = 5) during the 30-hour dissolution period (table 2). The initial 
burst was highest, 34%, from monoliths prepared at pH = 1 and lowest, about 6% from 
monoliths prepared at pH = 2.3. The diffusional exponent (n) characteristic for the 
release mechanism varied between 0.23 (pH = 1) to 0.61 (pH = 2.3) (III, table 2). 
 
Decreasing the water/TEOS ratio of the silica sol from 28 to 6 decreased the released 
amount of dexmedetomidine from about 64% to 30% during a 30-hour dissolution 
period (table 2, III, fig 2). Drug release could be regarded as diffusion controlled from 
silica xerogel monoliths synthesised at pH = 2.3 having r = 14 (n = 0.61) and r = 28 (n 
= 0.56). From r = 6 silica xerogel the exponential coefficient clearly deviated from 
diffusional release mechanism (n = 0.71) (III, table 2).  
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At the end of the dissolution test (30 h) about 83 % (pH = 2.3) to 75% (pH = 1 and pH 
= 3) of the matrix remained when the water/TEOS ratio was 14 (table 2, III, fig 1). 
When the water/TEOS ratio was changed from r = 6 to r = 28 the amount of matrix 
remaining after 30 hour varied between about 82 % (r = 6) and 80 % (r = 28) at pH = 
2.3 (table 2, III, fig 2).  
 
Microparticles. Scanning electron microscopy analysis showed that microparticles 
prepared at pH = 2.3 (r = 14) containing either dexmedetomidine HCl or toremifene 
citrate were spherical and had a smooth surface without visible pores on the surface 
(II, fig 1). Microparticles containing dexmedetomidine HCl spray-dried from a sol 
synthesised at pH = 1 with a water/TEOS ratio of 14 had, however, a rough surface 
(V, figure 1c). The size of microparticles containing toremifene citrate or 
dexmedetomidine HCl and prepared at different pH had a very similar, a quite narrow 
particle size distribution between 1.2 µm (D 10%) and 42 µm (D 90%) (II, table 2, V, 
table 2). The specific surface area of the microparticles was less than 10 m2/g (II, table 
2). 
 
Microparticles containing dexmedetomidine HCl were synthesised at same pH values 
as monoliths (pH = 1, pH = 2.3, pH = 3 and pH = 5) at a water/TEOS ratio of 14 (V). 
The release rate of dexmedetomidine was slowest from microparticles prepared at pH 
= 2.3 (HCl as catalyst) and pH = 3 (CH3COOH as catalyst) near the IEP of silica. The 
burst effect increased from microparticles prepared above or below the isoelectric 
point (table 2, V, fig 2). The amount of released dexmedetomidine varied between 
about 10 % (pH  = 2.3 and pH = 3) and 40 % (pH = 1) during a 30-hour dissolution 
period (table 2). When the synthesis pH was at IEP, the released amount during a 30-
hour dissolution period was so low that drug release kinetics could not be evaluated. 
Below or above IEP the slopes (n) of log Q vs. log t plots deviated from diffusion 
controlled release kinetics (n < 0.5) (V, table 3).  
 
The rate of dexmedetomidine release was significantly decreased from silica xerogel 
microparticles with increasing dilution of the sol before spray drying (V, fig 4). 
Decreasing the mole ratio of water/TEOS from 35 to 6 increased the amount of 
dexmedetomidine released from about 0.5% to 71% at 30 hours from microparticles 
prepared at pH = 2.3 (table 2, V, fig 4). Dexmedetomidine release obeyed zero order 
kinetics from microparticles prepared at water/TEOS ratios 6 as determined from the 
slope (n) of logQ versus logt plots (V, table 3). However the slope of the logQ vs. logt 
plot could not be reliably calculated for release profiles of water/TEOS ratios between 
10 and 35, because the released amount during a 30-hour dissolution period was too 
low. 
 
The synthesis pH as well as the water/TEOS ratio clearly affected the degradation rate 
of silica gel microparticles (V). After a 30-hour dissolution period about 99 % (pH = 3 
and pH =2.3) to 83 % (pH = 5) of the matrix remained (table 2, V, fig 3). The amount 
of matrix degraded during a 30-hour dissolution period varied between 20 % to 0.3%, 
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when the water/TEOS ratio (pH = 2.3) varied between 6 and 35 respectively (table 2, 
V, figure 5).  
 
5.1.3. Alkyl-substituted silica gel  
 
Monoliths. One object of study was the partial substitution of TEOS with alkyl-
substituted alkoxides (5, 10 or 25 mol-%) with covalently bound methyl (METES and 
DMDES) or ethyl groups (ETES) on the release rate of dexmedetomidine. The 
addition of METES did not have any effect on the release rate of dexmedetomidine 
(table 2, IV, fig1). Partial substitution with 10 or 25 mol-% of ETES decreased the 
released amount of dexmedetomidine from 44% (100% TEOS, pH = 2.3, water/TEOS 
14) to 37 and 22% respectively (table 2, IV, fig 1). An almost 3-fold decrease in 
released amount of dexmedetomidine during 30-hour dissolution was obtained, when 
the TEOS was substituted with 25 mol-% of DMDES having two covalently bound 
methyl groups attached to silicon (table 2, IV, fig 1). A long-term study showed that 
80 % of the drug was released from the matrix substituted with 25 mol-% of DMDES 
during four-month release test (IV, fig 2). The release obeyed diffusion controlled 
kinetics from monoliths containing 25 mol-% of METES, ETES or 100% TEOS (0.5 
< n < 0.63, IV, table 1). The release of dexmedetomidine deviated from diffusion 
controlled kinetics (n > 0.6) from rods containing 25 mol-% DMDES or 10 or 5 mol-
% of METES or ETES as determined from the slope (n) of the log Q vs. log t plots. 
The release conformed to zero order release from silica gels substituted with 5 or 10 
mol-% DMDES (IV, table 1).  
 
The amount of silica xerogel left after a 30-hour dissolution period varied between  
about 98% (25 mol% DMDES or ETES) and 87 to 85% (5 mol% of alkyl-substituted 
alkoxide) (table 2, IV, fig 3). 
 
Microparticles. Alkyl-substituted silica xerogel microparticles were spherical with 
aggregated clusters, the size distribution ranging from 1.36 to 35.02 µm (IV, table 2, 
fig 4) 
 
As compared to 100% TEOS, microparticles with a lag time in drug release, partial 
substitution with alkyl-substituted alkoxides DMDES or METES (5 mol-% and 25 
mol-%) increased the amount of released dexmedetomidine after one hour to about 3 
to 15% (table 2, IV, fig 5a). After the burst the drug was released nearly at the same 
rate as from 100% TEOS microparticles.  
 
The degradation of the silica microparticles, co-hydrolysed with 5 mol-% of alkyl-
substituted alkoxide (METES or DMDES) or with 25 mol-% DMDES, was faster than 
that of the 100% TEOS matrix synthesised at pH = 2.3 at water/TEOS ratio 14 (table 
2, IV, figure 5b). The amount of matrix remaining after dissolution was between 99% 
(25 mol-% METES) and 95 % (5 mol-% DMDES or METES) (table 2). 
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Table 2. In vitro release data for dexmedetomidine from silica gel monoliths and 
microparticles and degradation of silica gel (III – V). 
Formulation Dexmedetomidine 
released after one 
hour, % 
Dexmedetomidine 
released after  
30 h, % 
Silica gel  
degraded 
after 30 h, % 
pH  
(water/TEOS 14) 
   
Monoliths (III)    
pH = 1 34.1 71.1 25.5 
pH = 2.3 6.4 43.8 16.9 
pH = 3 13.6 77.7 25.7 
pH = 5 21.9 92.2 21.7 
Microparticles (V)    
pH = 1 21.5 41.4 13.6 
pH = 2.3 0 11.5 1.2 
pH = 3 0 7.3 0.7 
pH = 5 10.3 34.0 16.7 
Water/TEOS (r) 
(pH = 2.3) 
   
Monoliths (III)    
r = 6 2.5 30.2 17.8 
r = 14 6.4 43.8 16.9 
r = 28 8.9 63.6 20.4 
Microparticles (V)    
r = 6 0.9 71.1 20.0 
r = 10 0 26.7 2.8 
r = 14 0 11.5 1.2 
r = 28 0 3.0 0.4 
r = 35 0 0.5 0.3 
Alkyl substitution    
Monoliths (IV)    
25 mol-% DMDES 1.7 15.7 1.3 
10 mol-% 0.6 33.5 5.7 
5 mol-% 0.04 34.8 14.9 
25 mol-% METES 7.8 (2h) 48.7 5.8 
10 mol-% 2.8 43.3 11.5 
5 mol-% 1.8 41.5 14.3 
25 mol-% ETES 4.1 21.7 2.1 
10 mol-% 3.8 36.7 7.8 
5 mol-% 1.8 46.0 13.2 
Microparticles (IV)    
25 mol-% DMDES 8.1 29.4 3.5 
5 mol-% 15.0 40.2 5.4 
25 mol-% METES 3.3 15.5 1.3 
5 mol-% 4.0 17.9 5.8 
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5.1.4. Drug concentration 
  
The release rate of dexmedetomidine from silica gel monoliths was proportional to the 
drug concentration between 0.5 and 1 wt-% in the sol, corresponding to 3.9 and 7.7 
wt-% in the dry gel in monoliths, whereas the released amount seemed to be slightly 
lower from monoliths containing 15.4 wt-% of dexmedetomidine HCl (corresponding 
to 2 wt-% in the silica sol)(III, fig 3). From alkyl-substituted matrix (25 mol-% 
DMDES/75 mol-% TEOS), however, the release of dexmedetomidine was faster from 
monoliths containing 2 wt-% of dexmedetomidine HCl  in the sol (15.4 wt-% in dry 
gel) than from monoliths containing 1 wt-% of drug in the sol (7.7 wt-% in dry gel) 
(IV, fig 6b).  
 
The release of toremifene from silica gel microparticles was linear with respect to the 
square root of time up to 15.4 wt-% of drug in silica gel (II, fig 2), whereas release of 
dexmedetomidine was linear with respect to the square root of time when the drug 
concentration was 9.6 wt-% or lower (II, fig 3). The release rate of toremifene 
remained about the same when the concentration of drug was below 15 wt-%. The 
burst of toremifene increased appreciably when the drug concentration was 19.3 wt-% 
or above. For dexmedetomidine the release rate was the same when the drug 
concentration was 3.9 wt-% or 5.8 wt-% (II, fig 3). Above 5.8 wt-% of 
dexmedetomidine HCl, the drug release rate had a tendency to increase with 
increasing drug concentration. In addition, release of dexmedetomidine was slower 
than that of toremifene when the drug concentration was below 11.6 wt-% (II, fig 2-4).  
 
 
5.2. TISSUE EFFECTS OF SUBCUTANEOUSLY ADMINISTERED 
SILICA XEROGEL IN MICE 
 
The local effect of the silica xerogel implant was restricted to the immediate vicinity 
of the implant. A well-organised fibrous capsule was formed around the implant from 
14 days time point onward (I, fig 4a). The implant did not cause necrosis and the 
inflammatory response observed was mainly due to a minor infiltration of 
macrophages at time points 14 days and later. Acute inflammation was observed only 
at the 7-day point. Phagocytic macrophages were present close to the implant at 14 
days or later (I, fig 4b). No accumulation of dissolved material occurred. No extensive 
silica xerogel related histological changes could be observed in the liver, lymph nodes 
or kidney at the 1.5 g/kg dose. 
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5.3. DRUG RELEASE IN VIVO  
 
5.3.1. Toremifene release in mice  
 
Toremifene was released in a sustained manner from silica xerogel monoliths in mice. 
The amount of 3H-toremifene remaining in the monolith as determined by dissolving 
the excised monolith in NaOH and measuring the radioactivity, was about 16% after 
42 days from implantation (I, fig 2). About 40% of the loaded amount eluted during 
the first week. Weight loss of the matrix was about 75 % during the test period, 42 
days (I, fig 2). The release rate of toremifene in mice was lower than in vitro where 
about 90% of the loaded amount was released after 99 hours (I, fig 1). The amount of 
silica released is equivalent to about 65% weight loss of the total silica xerogel 
monolith weight (I, fig 1).  
 
The radioactivity of tritiated toremifene was detected up to 42 days in the liver, 
kidneys, and lung. The radioactivity reached a maximum value at 14 days and then 
remained relatively constant until the end of the implantation test. The original data 
showed that radioactivity was not found in the blood or uterus (I, fig 3). Toremifene 
induced uterine glandular hyperplasia, the characteristic hormonal change seen in 
mice treated with this drug, was observed at all studied time points.  
 
5.3.2. Bioavailability of dexmedetomidine in dogs  
 
Table 3 presents a summary of mean pharmacokinetic parameters resulting from a 
subcutaneous administration of alkyl-subsituted silica gel monoliths (IV) containing 
dexmedetomidine HCl at two dose levels (4.15 mg dexmedetomidine HCl and 8.9 mg 
dexmedetomidine HCl), microparticle suspension (containing 4.6 mg of 
dexmedetomidine HCl) (V) and a reference dose at two dose levels (0.05 mg and 0.1 
mg dexmedetomidine HCl in 0.9 % NaCl solution). The relative bioavailability was 
calculated using a dose of 0.05 mg as reference for alkyl-substituted silica gel 
monoliths and a dose of 0.1 mg as a reference for microparticles.  
 
The Cmax value after the lower dose of the alkyl-substituted silica gel monoliths was 
0.6 ng/ml and that of the higher dose was 3.8 ng/ml (table 3, IV, fig 6). The Cmax after 
microparticle formulation containing approximately the same amount of 
dexmedetomidine as the lower dose of monoliths was about 1.6 ng/ml (table 3, V fig 
6). The mean maximum concentration was achieved at about 5 hours after 
administration of silica gel formulations whereas it was reached at about one hour 
after administration of the references.  After the reference, the dexmedetomidine 
concentration declined rapidly, decreasing below the quantitation limit after six hours. 
In contrast, measurable serum concentrations were still seen in serum samples taken 
48 hours after the dosing of alkyl-substituted silica gel monoliths or silica gel 
microparticles (IV, fig 6; V, fig 6). The concentration of dexmedetomidine in serum 
after 48 hours was 0.09 ng/ml for 4.15 mg and 0.23 ng/ml for 8.9 mg of 
dexmedetomidine HCl in alkyl-substituted silica gel. After the administration of 4.6 
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mg of dexmedetomidine HCl in the microparticle formulation, the serum 
concentration was 0.13 ng/ml after 48 hours.  
 
Table 3. The pharmacokinetic parameters after subcutaneous administration of 0.1 mg  
or 0.05 mg of dexmedetomidine HCl as reference, 4.6 mg of dexmedetomidine HCl  
incorporated into silica gel microparticles (100 mol-% TEOS, pH = 2.3, r = 14) and 
4.15 mg or 8.9 mg incorporated into alkyl-substituted  (25 mol-% DMDES) silica 
xerogel monoliths in dogs. Means ± SD . 
Parameter Reference  
0.05 mg  
(n = 4) 
Reference  
0.1 mg 
(n = 4) 
Microparticles 
4.6 mg   
(n =3) 
Alkyl-
substituted 
4.15 mg  
(n = 4) 
Alkyl-
substituted 
8.9 mg 
 (n = 3) 
C max 
(ng/ml) 
0.5 (0.3) 1.3 (0.5) 1.6 (0.6) 0.6 (0.3) 3.8 (0.5) 
Tmax (h) 1.1 (0.6) 1.5 (0.6) 4.7 (1.2) 5.0 (1.2) 5.3 (2.3) 
AUC0-48h 
(ng*h/ml) 
0.98 
(0.24)* 
3.31 
(0.95)* 
24.8 (7.7) 9.8 (2.5) 67.9 (12.9) 
Relative 
bio- 
availability 
1.0 1.0 0.16 0.12 0.39 
Cmax = peak concentration of dexmedetomidine, tmax = time to reach Cmax,  
AUC0-48h = area under the concentration vs. time curve 
*AUC0-8h 
 
 
6. DISCUSSION 
 
6.1. CONTROLLING THE RELEASE RATE OF MODEL DRUGS AND 
DEGRADATION OF SILICA GEL BY SYNTHESIS 
PARAMETERS AND MANUFACTURING METHOD  
Silica sol is mostly manufactured to monoliths by casting. Spray drying was evaluated 
as an alternative method for the manufacturing of silica gel and as a means to control 
the release rate of drug substances. During spray drying silica sol is forced to 
condense very quickly at an increased temperature, whereas monoliths are allowed to 
polymerise spontaneously during a longer time period. The difference in the 
polymerisation process leads to changes in the inner structure of the silica gel. 
Microparticles have a condensed structure with a specific surface area < 10 m2/g (II, 
table 2), which is significantly lower than that of typical porous monoliths (≈ 400 
m2/g) (Ahola et al., 2000). The structure of silica gel and the release rate of 
dexmedetomidine from monoliths and microparticles were controlled by synthesis 
factors. In general the porous structure of cast silica xerogel monoliths resulted in a 
faster release of drug and degradation of the matrix as compared to spray-dried 
microparticles. The release of dexmedetomidine from monoliths prepared at various 
pH levels and water/TEOS ratios varied from days to a few weeks, whereas with 
microparticles it was from a few days to several months. Drug release was faster than 
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the degradation of the silica matrix, which varied from days to months with monoliths 
and from days to more than a year with microparticles as calculated on the basis of the 
30-hour dissolution period results in table 2 (Table 4). The major differences between 
monoliths and microparticles are highlighted in table 4 and discussed in detail below. 
 
Table 4. Comparison of main properties of sol-gel processed silica gel monoliths and 
microparticles 
Property Monolith Microparticles 
Drug concentration < 35 wt-% (Ahola et 
al., 2000) 
< 15 wt-% 
Specific surface area  ≈ 400 m2 (Ahola et al., 
2000) 
< 10 m2 
Optimum synthesis pH Between pH = 2-3 Between pH =2-3 
Release kinetics of drug Diffusion Zero order (at IEP) 
Release time of 
dexmedetomidine* 
Release kinetics of SiO2  
From days to weeks 
 
Zero order 
From days to months 
 
Zero order 
Appr. degradation time  
of silica gel* 
From days to months* From days to more than a 
year* 
*Release time of dexmedetomidine and degradation time of silica gel are calculated on the 
basis of a 30 hour dissolution period results described in table 2 
 
 
6.1.1. Sol-gel synthesis parameters 
 
6.1.1.1. pH and water/TEOS ratio 
The optimum release profile for dexmedetomidine was obtained from silica gels 
(monoliths and microparticles) prepared at the isoelectric point of silica (pH = 2.3 and 
pH = 3) where the structure of silica gel is most condensed (Brinker and Scherer, 
1990) (III, V). The amount of dexmedetomidine released after the dissolution period 
(30 h) was greater with a decreasing diameter of the rod (II, fig 4). Similar results 
were obtained with bulk degrading polymers (Tamada and Langer, 1993, Lemmouchi 
and Schacht, 1997). Changing the water /TEOS ratio of the starting materials from 6 
to 35 with microparticles and from 6 to 28 with monoliths at the pH = 2.3 had an 
opposite effect on the release of dexmedetomidine from microparticles and from 
monoliths. The amount of released dexmedetomidine from microparticles decreased 
140-fold when silica sol was diluted with water during a 30-hour dissolution period 
(table 2, V, fig 4). Contrary to microparticles, the amount of released 
dexmedetomidine increased by appr. 50% from monoliths with an increasing 
water/TEOS ratio (table 2, III, fig 2). Previously Aughenbaugh and co-workers 
(Aughenbaugh et al., 2001) have observed that an increasing water/TEOS ratio 
increased the release rate of vancomycin from silica xerogel monoliths. It is well 
known that the water/TEOS ratio affects the structure of silica gel monoliths and a 
more condensed matrix is formed at low water/TEOS ratios (Meixner and Dyer, 
1999). However, during spray drying, silica particles are forced to form quickly from 
   
 33
the sol at elevated temperatures. Dilution of the sol influences several factors and the 
main effect is that the volume fraction of the solids and viscosity of sols are decreased. 
In addition, some attraction is needed to form dense particles at a colloidal level. It is 
also known that due to exceedingly strong attraction, the particles stick together 
tightly where they first make contact and more open structures are easily formed. 
However, dilution decreases the attractive forces between colloidal silica particles 
causing a more dense packing at high water/TEOS ratios. Thus the sol diluted with an 
increasing amount of water produces slower degrading silica particles and slower drug 
release.  
 
Modification of the matrix by changing the processing method from casting to spray 
drying changed the drug release mechanism. The release of dexmedetomidine was 
mainly diffusion controlled from 100% TEOS monoliths (III, table 2), whereas zero 
order release was obtained from certain microparticle formulations  (V, table 3).  The 
diffusional coefficient calculated from the slope of the log (released drug) versus log 
(time) plot and describing the release mechanism of dexmedetomidine varied between 
0.2< n < 0.7 for monoliths prepared at various pH and water/TEOS ratios, whereas it 
was between 0.2 (for microparticles prepared at pH = 1 and pH = 5) and about 1.0 (for 
microparticles prepared at pH = 2.3 with water/TEOS ratio 6). Values below 0.5, 
however, indicate porous structure (Peppas, 1985). The release of dexmedetomidine 
gave values below 0.5 from monoliths and microparticles prepared at pH = 1 and pH = 
5, where the structure of the silica xerogel matrix is more porous than at the isoelectric 
point causing an increased burst and a faster drug release rate (Curran and Stiegman, 
1999). More mesoporous structure is formed due to higher condensation rate with 
monoliths when the pH deviates from IEP. Microparticles prepared at pH = 1 or pH = 
5 are probably more porous than microparticles prepared at IEP because of repulsion 
preventing formation of dense particles at colloidal level. This difference in structure 
is also showed in SEM pictures where the surface of microparticles prepared at pH = 1 
is more rough (V, fig 1). 
 
6.1.1.2. Alkyl-substituted  silica gel 
The structure of the silica xerogel matrix can be modified by adjusting the amount of 
alkyl-substituted siloxane. Organic groups linked to the oxide network by stable 
chemical bonds change the porosity by lowering the degree of cross-linking and 
provide decreased hydrophilicity and ion exchange capacity due to the decreased 
amount of surface silanol groups (Schmidt, 1989, Mah and Chung, 1995, Lev et al., 
1995). The pore size of the silica gel matrix increases with increasing length of the 
alkyl group (Kusakabe et al., 1999). It is known from previous studies that the release 
rate of active agents can be modified by chemical modification of the silica xerogel 
matrix (Unger et al., 1983, Böttcher et al., 1998, Ahola et al., 2001). In the present 
study, a decrease in the release rate of drug and in initial bursts was dependent on the 
amount of the alkyl-substituted alkoxide as well as on the length and number of the 
functional groups attached covalently to silicon (table 2, IV, fig 1). The observed 
decrease in release rate may be due to hydrophobic nature of ethyl and methyl groups 
or due to changes in the porous structure of silica gel depending on the amount and 
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type of alkoxide. Interactions of dexmedetomidine with the silica gel also influence 
the release rate. Dexmedetomidine probably binds to silica gel with hydrogen bonds 
and with hydrophobic interactions (Iler, 1979).  
 
Value of the diffusional coefficient varied between 0.52 < n < 1.06 for alkyl-
substituted silica gel monoliths. With 25 mol-% of alkyl-substitution the release was 
diffusion controlled (n = 0.52-0.71) but changed with 5 or 10 mol-% of alkyl-
substitution towards non-Fickian or zero order release (n = 0.72-1.06) (IV, table 1). By 
adjusting the alkyl-substituted alkoxide/TEOS ratio upward, a decreased ion exchange 
capacity, an increased hydrophobicity and porosity is gained (Kusakabe et al., 1999). 
The modifications in the silica gel structure cause also changes in the release 
mechanism of dexmedetomidine.  
 
The effect of alkyl-substitution on the release profile of dexmedetomidine from 
microparticles was that the burst increased from DMDES and METES substituted 
microparticles compared to 100% TEOS microparticles and the effect was more 
pronounced with DMDES (IV, fig 5a). This may indicate that alkyl-substituted 
microparticles have a more open structure than 100% TEOS microparticles due to 
covalently bound alkyl groups that prevent formation of a dense structure during spray 
drying. They may also be too hydrophobic to keep dexmedetomidine HCl in the silica 
gel structure during spray drying.  
 
6.1.2. Drug concentration 
 
Dexmedetomidine is apparently in dissolved form in silica gel monoliths. Thus the 
release of the drug substance should be proportional to the drug concentration (Baker, 
1987). However, the release of dexmedetomidine from monoliths was proportional to 
the dexmedetomidine concentration when the drug concentration was 0.5 or 1 wt-% in 
the sol corresponding to 3.9 or 7.7 wt-% in silica xerogel, whereas the release rate 
decreased from monoliths containing 15.4 wt-% of drug  (III, fig 3). In an earlier study 
the release of toremifene from a silica gel monolith was proportional to the drug 
concentration between 1.9 and 5.5 wt-% in the sol corresponding to concentration 
between 11.4 wt-% and 34.4 wt-% in dry silica gel (Ahola et al., 2000). However, 
from alkyl-substituted silica gel monoliths dexmedetomidine released at higher rate 
from rods containing higher amount of dexmedetomidine. This is possibly due to 
modified ion exchange capacity and polarity of the silica xerogel meaning that the 
loading capacity of organomodified silica xerogel could be lower than that of 
unmodified silica xerogel 
 
Drug release from microparticles was studied both with toremifene citrate and 
dexmedetomidine HCl. The release rate of dexmedetomidine was slower than that of 
toremifene when the drug concentration was below 11.6 wt-% (II, fig 2 - 4). This 
could be due to the difference in physicochemical properties of drugs. Unger and co-
workers have earlier reported that the basic drugs act as external catalysts, increasing 
the release rate of the drug in the concentration and in a pKa dependent manner 
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(Unger et al., 1983). Toremifene citrate is more hydrophobic, a stronger base, less 
soluble and has probably less hydrogen bonding capacity than dexmedetomidine. In a 
forced spray drying process toremifene does not stay in dissolved form and 
precipitates more easily than dexmedetomidine on the air/sol interface of silica 
microparticles. This precipitation tendency may cause an increasing release trend for 
both drugs in the amount of drug released during the first hour from microparticles 
when the concentration of drug increases (II, fig 2 and 3). The release profile of 
toremifene deviated from the diffusion controlled release at drug concentration above 
19 wt-% and the burst was increased to more than 20 % (II, fig 2). The drug loading 
capacity of microparticles was also shown to be lower than that of monoliths, where 
the release rate of toremifene was proportional to the drug concentration up to 34.4 
wt-% (Ahola et al., 2000).  
 
6.1.3. Degradation of the silica gel 
 
According to the literature on the subject, the degradation of a silica matrix is linear 
with time and generally slower than the release rate of drugs (Ahola et al., 2000, 
Ahola et al., 2001). In studies described in this thesis the degradation of silica gel 
appeared to have a lag phase before degradation begun (III, fig 1, 2 and 4; IV, fig 3). 
For monoliths prepared by co-hydrolysis of TEOS with alkyl-substituted alkoxides, 
the lag time might be due to the hydrophobic structure of the silica gel.  
 
The lifetime of the silica gel microparticles varied between about 6 days (r = 6, pH = 
2.3) and a year and half (r = 35, pH = 2.3) as calculated from the in vitro dissolution 
results showed in table 2. Microparticles prepared at IEP have a dense structure and 
diluting the sol from water/TEOS ratio 6 to 35 leads to even denser particles. The 
degradation time of the monoliths prepared with different water/TEOS ratio, at 
different pH or in different size varies between 4 and 8 days. Larger silica gel 
monoliths degraded faster than smaller ones, giving approximately equal erosion 
times. The degradation rate of the monolithic matrix seemed to be dependent on the 
total amount of material, suggesting that the SA/V ratio (surface area to volume ratio 
of the device) defines the erosion rate (Tamada and Langer, 1993, Grizzi et al., 1995). 
Monoliths substituted with 25 mol-% of DMDES and showing the slowest 
degradation rate among alkyl-substituted silica xerogels degraded in about 4 months 
(table 2). The degradation rate of alkyl-substituted silica gels was dependent on the 
amount and type of the alkyl-substituted alkoxide (table 2). These results show that the 
degradation rate of the silica xerogel can be modified by varying the composition of 
starting materials and subsequently the structure of the silica gel matrix or by varying 
the manufacturing method from casting to spray drying.  
 
The in vivo degradation time of a monolith (r = 14, pH = 2.3) weighing appr. 15 mg is 
about 2 months (I, fig 2). This means that the degradation time in vivo is longer than 
in vitro, which was about 8 days as calculated from the in vitro dissolution profile (I, 
fig 1). This difference between degradation rates is partially due to serum proteins that 
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bind onto the surface of silica gel preventing the dissolution of the material in vivo 
(Falaize et al., 1999). 
 
 
6.2. IN VIVO STUDIES 
 
6.2.1. Tissue effects 
 
The plain silica xerogel implant (without drug substance) did not cause irritation of the 
surrounding tissue during 42-day treatment in mice (I, fig 4a). Effects at the 
implantation site were considered part of a normal wound healing process. The final 
stage of the healing was the development of a fibrous capsule around the implant at 
14-d point. The end-stage healing response to biomaterials is generally fibrous 
encapsulation, which is typically considered a sign of biocompatibility (Anderson et 
al., 1981, Anderson, 1994).  
 
Subcutaneously implanted untreated silica xerogel as well as bioactive glass are 
surrounded by of a thin to medium thick fibrous capsule containing only few 
inflammatory cells at the tissue implant interface after 4 weeks (Hench and Wilson, 
1986, Radin et al., 1998, Gerritsen, 2000). The proliferation of cultured murine 
fibroblasts and activation of human polymorphonuclear leukocytes by sol-gel derived 
glasses has also been studied. Sol-gel glass neither caused the inhibition of fibroblast 
growth nor induced a significant inflammatory response by polymorphonuclear 
leukocytes (Wilson et al., 1981, Palumbo et al., 1997). 
 
No silica related histological changes in liver, kidney, lymph nodes and uterus were 
detected during the test period even though the amount applied was high (1.5 g/kg 
body weight) (I). Lai and co-workers have measured the release of silica from glass 
implants and the distribution of dissolved silica to various organs in the body. They 
found that silica is excreted in the urine through kidneys or is actively phagocytised by 
the macrophages (Lai et al., 1998).  
 
6.2.2. Toremifene release in mice  
 
About 40 % of toremifene was released during the first seven days and resulted in the 
peak radioactivity at 7 to14 days and after that radioactivity in various organs was 
quite steady for the rest of the implantation time (42 days) (I, fig 3). Sustained release 
of toremifene was obtained for more than six weeks (I, fig 2). The results were similar 
to earlier studies where progesterone incorporated during sol-gel synthesis or 
toremifene citrate impregnated into heat-treated silica xerogel was administered 
subcutaneously in rats or mice (Sieminska and Zerda, 1996, Kortesuo et al., 1999). 
After an initial burst effect the release rate was nearly constant for more than 4 weeks.  
 
The fibrous capsule around the implant may function as a permeability barrier and 
decrease the drug release from the implantation site to the systemic circulation 
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(Anderson, 1994).  Toremifene related changes in the uterus were detected at all time 
points. However, the amount of toremifene in the implants was high, 350 mg/kg. It is 
possible that only part of the drug diffused through the fibrous capsule, which is, 
however, enough to cause characteristic changes in the uterus.  
 
6.2.3. Bioavailability of dexmedetomidine in dogs 
 
The rate and amount of bioavailability of dexmedetomidine was clearly reduced from 
silica gel microparticles or alkyl-substituted silica gel monoliths as compared to the 
reference dose (table 3). The relative bioavailability was slightly higher with 
microparticles containing 4.6 mg of dexmedetomidine (0.16) than with alkyl-
substituted monoliths containing 4.15 mg of dexmedetomidine (0.12) (table 3). The 
Cmax value was appreciably higher with microparticle formulation than with alkyl-
substituted silica gel monoliths containing appr. the same amount of dexmedetomidine 
HCl (table 3). However the duration of effect was similar. Alkyl-substituted silica gel 
is hydrophobic and thus diffusion of tissue fluid in to the matrix and the subsequent 
release of drug may be prevented. On the other hand, microparticles are widely spread 
in the subdermal tissue after the hypodermal injection and this probably facilitates 
drug release. The comparison of Cmax and AUC values shows that a two-fold increase 
in dexmedetomidine HCl concentration in alkyl-substituted silica xerogel formulations 
resulted in a 7-fold increase in Cmax and AUC values in dogs (table 3, IV, fig 6a). This 
supra-proportional increase might be due to faster release of dexmedetomidine from 
formulations with a greater amount of dexmedetomidine HCl (IV, fig 6b).  
 
The reduced biovailability of dexmedetomidine from silica gel formulations as 
compared to reference, may be due to the condensed non-porous structure of silica 
microparticles or the hydrophobicity of the alkyl-substituted matrix of monoliths. 
Dexmedetomidine that was absorbed into the body during the test period was possibly 
released from the surface of the silica xerogel formulation. Most of the drug, however, 
is incorporated inside the silica structure and is released as the matrix degrades. In 
order to keep the serum concentration on the desired level, the release rate should be 
faster, because the elimination half-life of dexmedetomidine is short, about 1h and 
therefore it eliminates faster than more drug substance is released from the 
formulation to the circulation (Li et al., 1988, Salonen, 1989).  
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6.3 SOL-GEL DERIVED SILICA MONOLITHS AND 
MICROPARTICLES AS A POTENTIAL DRUG DELIVERY 
MATRIX IN TISSUE ADMINISTRATION 
 
The applicability of sol-gel derived silica gel was studied as an implantable or 
injectable matrix for controlled drug delivery. Various means to control the structure 
and the release rate of drugs in vitro and in vivo were studied. An ideal matrix used in 
tissue administration should possess the following characteristics. 1) It should have an 
accurate and precise release profile and 2) be biocompatible in vivo and have a 
predictable in vivo degradation rate. 3) It should be comfortable to the user with the 
relevant indication and 4) should be easily administered. The system should possess 5) 
an adequate reservoir capacity and 6) be safe, free from leaks and dose dumping and 
also adaptable for drug substances with different physicochemical properties. In 
addition, the production method should be capable, robust and preferably cost-
effective.  
 
Sol-gel technology is a gentle room temperature process. Different active agents 
including proteins and other macromolecules retain their biological activity in the sol-
gel processed silica gel matrix (Nicoll et al., 1997, Ahola et al., 2001). 
Physicochemical properties, such as solubility, hydrophobicity and pKa of the 
releasing drug seem to affect the drug release behaviour in vitro. The solubility of 
drug into silica sol is a factor that has to be taken into account with each new drug 
candidate. If the solubility is low, the drug may crystallise during the gelation and 
drying steps causing an inhomogeneous distribution and non-constant release of drug. 
Release rates of the model drugs toremifene citrate and dexmedetomidine HCl were 
controlled by varying the sol-gel synthesis parameters or by the manufacturing 
method. The drug release was prolonged, constant and conformed to zero order release 
from certain spray-dried microparticles and alkyl-substituted silica gel monoliths. 
From 100% TEOS monoliths the release was quite rapid and occurred mainly by 
diffusion. The release rate of dexmedetomidine could be controlled over periods 
lasting from days to more than a year in vitro. Silica gel was shown to be 
biodegradable and did not cause adverse effects in the surrounding tissue or organs 
studied, although the amount of silica gel was quite significant. Silica xerogel, either 
cast or spray dried, did not cause dose dumping and was easily administered with a 
hypodermic needle into the desired area.  
 
Nowadays silica based material is used in biomedical applications. Consequently 
silica xerogel, especially silica gel microparticles and alkyl-substituted silica gel 
monoliths seem to be promising material for a matrix in controlled drug delivery 
systems in tissue administration. However, there are open questions that could be 
solved in further studies in vitro as well as in vivo. These include the applicability of 
sol-gel techniques for drugs with different physicochemical properties, long-term 
stability studies and safety tests. The preparation of silica xerogel in laboratory scale 
was quite trouble-free but in industrial scale it is more demanding and especially the 
production of sterile silica gel products requires special equipment and facilities.  
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7. CONCLUSIONS 
 
The following conclusions can be drawn on the basis of the results of the studies. 
 
1. The preliminary implantation study showed that silica xerogel degraded in the 
body and did not cause adverse reactions in various organs or at the implantation 
site in mice. 
 
2. Various injectable and implantable silica gel formulations for controlled drug 
delivery were developed. The release rate of model drugs, toremifene and 
dexmedetomidine and degradation of the silica gel matrix was controlled by 
synthesis parameters or by choice of manufacturing method. Release mechanism 
of dexmedetomidine was governed by diffusion from monoliths and obeyed zero 
order release in certain microparticle and alkyl-substituted formulations in vitro.  
 
3. Sustained release was achieved with toremifene in mice and with 
dexmedetomidine in dogs. A sustained release silica gel formulation for 
toremifene citrate with an effect duration in excess of six weeks and a formulation 
for dexmedetomidine with an effect duration of 24 hours were developed. 
Toremifene and dexmedetomidine were released with simultaneous degradation of 
silica matrix. The degradation rate of silica gel, however, was slower than the 
release rate of drugs. 
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